Biosurgery Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Biosurgery Market Size

Biosurgery Market size is projected to grow at a substantial rate from 2024 to 2032, due to the increasing demand for minimally invasive surgical procedures. The rising aging population and the higher prevalence of chronic medical conditions is driving advancements in biosurgery product technologies. As per the WHO, the global population of individuals aged 60 years and above is projected to double by 2050, exceeding 2 billion.
 

The increasing health awareness, expanding healthcare expenditure, the growth of medical tourism, and rapid strides in healthcare infrastructure is projected to offer new opportunities for market development. Additionally, the notable rise in sports-related injuries and accidents is accelerating the need for advanced biosurgery. According to the World Stroke Organization and Lancet Neurology, without prompt intervention, the global stroke-related mortality rate is projected to surge by 50%, reaching 9.7 million deaths annually by 2050.
 

This increasing burden of brain strokes will escalate the demand for biosurgery products to provide effective medical intervention. However, the increasing reluctance of patients to visit hospitals considering the high risk of hospital acquired diseases (HAIs) may limit the industry progress in the forthcoming period.
 

Biosurgery Market Trends

Minimally invasive surgeries, facilitated by advancements in surgical techniques and equipment. Increasing application of biosurgical products in various medical fields, such as orthopedics and cardiovascular surgery, is also expanding their utilization. For instance, in November 2023, Ethicon, a Johnson & Johnson MedTech company, received approval for ETHIZIA™, a clinically proven adjunctive hemostat solution effective in achieving sustained hemostasis in challenging bleeding scenarios.
 

Moreover, the growing focus on R&D activities and product innovations is driving the development of new biomaterials to enhance the effectiveness of biosurgical interventions. The growing prevalence of chronic diseases and the higher demand for personalized healthcare solutions will also increase the market appeal of biosurgery procedures.
 

Biosurgery Market Analysis

The hemostatic agents product segment is projected to witness notable gains through 2032. This is due to the rising prevalence of surgical procedures, increasing trauma cases, and the growing emphasis on effective hemostatic solutions. With surgical interventions becoming more common, the demand for advanced and efficient hemostatic agents is also rising. The continuous R&D efforts to enhance the efficacy of hemostatic agents.
 

The biosurgery industry value from the cardiovascular surgery segment is estimated to rise at substantial CAGR between 2024 and 2032. The progression can be attributed to the increasing incidence of cardiovascular diseases, rising demand for advanced surgical solutions, and technological advancements in biosurgery products. Moreover, the growing awareness about the benefits of biosurgery in cardiovascular procedures is leading to the high adoption of biosurgery solutions in cardiovascular surgeries.
 

The North America biosurgery market is projected to expand at robust rate from 2024 to 2032, due to the surge in surgical procedures, advancements in medical technologies, and an increasing prevalence of chronic diseases. Additionally, the well-established healthcare infrastructure and rising awareness among healthcare professionals about the benefits of biosurgery is increasing the product appeal in the region. Along with this, favorable reimbursement policies and the high adoption rate of innovative surgical techniques will augment the regional market expansion.
 

Biosurgery Market Share

Some of the major biosurgery companies are:

• Johnson & Johnson
• Baxter
• C.R. Bard
• BD
• Stryker Corporation
• Pfizer, and Medtronic.
   

Key players operating in the industry are targeting their efforts towards developing novel solutions to gain a higher ground in the industry. For instance, Baxter International Inc. is actively developing products for the treatment of kidney disease and various chronic and acute medical conditions.
 

Biosurgery Industry News:

• In March 2022, Molecular Matrix, Inc., a developer of osteobiologic technology for bone tissue regeneration, introduced Osteo-P Synthetic Bone Graft Substitute (BGS) designed for musculoskeletal systems.